These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


320 related items for PubMed ID: 11021742

  • 1. The role of caspase family protease, caspase-3 on cisplatin-induced apoptosis in cisplatin-resistant A431 cell line.
    Mese H, Sasaki A, Nakayama S, Alcalde RE, Matsumura T.
    Cancer Chemother Pharmacol; 2000; 46(3):241-5. PubMed ID: 11021742
    [Abstract] [Full Text] [Related]

  • 2. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
    Sawada S, Mese H, Sasaki A, Yoshioka N, Matsumura T.
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
    [Abstract] [Full Text] [Related]

  • 3. Analysis of cellular sensitization with cisplatin-induced apoptosis by glucose-starved stress in cisplatin-sensitive and -resistant A431 cell line.
    Mese H, Sasaki A, Nakayama S, Yokoyama S, Sawada S, Ishikawa T, Matsumura T.
    Anticancer Res; 2001 Jun; 21(2A):1029-33. PubMed ID: 11396136
    [Abstract] [Full Text] [Related]

  • 4. Regulation of apoptosis reduction in the cisplatin-resistant A431 cell line by Bcl-2 and CPP32.
    Mese H, Sasaki A, Alcalde RE, Nakayama S, Matsumura T.
    Chemotherapy; 2000 Jun; 46(1):69-76. PubMed ID: 10601800
    [Abstract] [Full Text] [Related]

  • 5. Differential effects of caspase inhibitors on TNF-induced necroptosis.
    Sawai H.
    Biochem Biophys Res Commun; 2013 Mar 15; 432(3):451-5. PubMed ID: 23410748
    [Abstract] [Full Text] [Related]

  • 6. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma.
    Seki K, Yoshikawa H, Shiiki K, Hamada Y, Akamatsu N, Tasaka K.
    Cancer Chemother Pharmacol; 2000 Mar 15; 45(3):199-206. PubMed ID: 10663637
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells.
    Toyozumi Y, Arima N, Izumaru S, Kato S, Morimatsu M, Nakashima T.
    Int J Oncol; 2004 Sep 15; 25(3):721-8. PubMed ID: 15289875
    [Abstract] [Full Text] [Related]

  • 9. Involvement of caspases in 5-FU induced apoptosis in an oral cancer cell line.
    Ohtani T, Hatori M, Ito H, Takizawa K, Kamijo R, Nagumo M.
    Anticancer Res; 2000 Sep 15; 20(5A):3117-21. PubMed ID: 11062731
    [Abstract] [Full Text] [Related]

  • 10. Apoptosis-inducing activity of cisplatin (CDDP) against human hepatoma and oral squamous cell carcinoma cell lines.
    Okamura M, Hashimoto K, Shimada J, Sakagami H.
    Anticancer Res; 2004 Sep 15; 24(2B):655-61. PubMed ID: 15161008
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line.
    Mese H, Ueyama Y, Suzuki A, Nakayama S, Sasaki A, Hamakawa H, Matsumura T.
    Chemotherapy; 2001 Sep 15; 47(2):136-42. PubMed ID: 11173816
    [Abstract] [Full Text] [Related]

  • 12. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
    Kim R, Tanabe K, Inoue H, Toge T.
    Int J Oncol; 2002 Mar 15; 20(3):549-55. PubMed ID: 11836567
    [Abstract] [Full Text] [Related]

  • 13. A cellular mechanism that reversibly inactivates pancaspase inhibitor zAsp-CH(2)-DCB: a potential pitfall causing discrepancy between in vitro and in vivo caspase assays.
    Sakurada K, Kitanaka C, Kokubu A, Tomiyama A, Sunayama J, Kayama T, Kuchino Y.
    Biochem Biophys Res Commun; 2002 Mar 08; 291(4):1022-30. PubMed ID: 11866468
    [Abstract] [Full Text] [Related]

  • 14. Comparative analysis of cell death induction by cisplatin and 5-FU in human oral squamous and hepatocellular carcinoma cell lines.
    Okamura M, Shimada J, Sakagami H.
    Anticancer Res; 2008 Mar 08; 28(1A):253-9. PubMed ID: 18383853
    [Abstract] [Full Text] [Related]

  • 15. Caspase-mediated activation of a 36-kDa myelin basic protein kinase during anticancer drug-induced apoptosis.
    Kakeya H, Onose R, Osada H.
    Cancer Res; 1998 Nov 01; 58(21):4888-94. PubMed ID: 9809995
    [Abstract] [Full Text] [Related]

  • 16. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
    Suzuki M, Endo M, Shinohara F, Echigo S, Rikiishi H.
    Cancer Chemother Pharmacol; 2009 Nov 01; 64(6):1115-22. PubMed ID: 19280190
    [Abstract] [Full Text] [Related]

  • 17. The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific.
    Kissel CK, Schadendorf D, Röckmann H.
    Melanoma Res; 2006 Dec 01; 16(6):527-35. PubMed ID: 17119454
    [Abstract] [Full Text] [Related]

  • 18. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
    Asselin E, Mills GB, Tsang BK.
    Cancer Res; 2001 Mar 01; 61(5):1862-8. PubMed ID: 11280739
    [Abstract] [Full Text] [Related]

  • 19. Ectopic p16(ink4) expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells.
    Fukuoka K, Nishio K, Fukumoto H, Arioka H, Kurokawa H, Ishida T, Iwamoto Y, Tomonari A, Suzuki T, Usuda J, Narita N, Saijo N.
    Int J Cancer; 2000 Apr 15; 86(2):197-203. PubMed ID: 10738246
    [Abstract] [Full Text] [Related]

  • 20. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M, Mizuguchi J.
    J Orthop Res; 2003 Sep 15; 21(5):949-57. PubMed ID: 12919886
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 16.